GoodRx Holdings (GDRX) investor relations material

Executive summary

• Achieved strong Q3 execution with measurable progress on strategic priorities, expanded partnerships, and new affordability and brand campaigns.

• Q3 2025 revenue was $196.0 million, up slightly from $195.3 million in Q3 2024, with net income of $1.1 million and a net income margin of 0.6%.

• Adjusted EBITDA for Q3 2025 was $66.3 million (33.8% margin), up from $65.0 million (33.3%) in Q3 2024.

• Acquired VCRX for $30.0 million and ScriptDrop for $13.5 million to expand prescription transactions and delivery capabilities.

• Over 6 million prescription-related consumers used the platform in Q3 2025, but Monthly Active Consumers declined to 5.4 million from 6.5 million a year ago.

Financial highlights

• Q3 total revenue reached $196 million, up $1 million year-over-year.

• Manufacturer solutions revenue grew 54% year-over-year to $43.4 million, driven by new and expanded brand partnerships.

• Adjusted EBITDA was $66.3 million, up 2% year-over-year, with a margin of 33.8%.

• Subscription revenue decreased 3% to $20.7 million, reflecting a drop in subscription plans to 671,000 from 701,000.

• Ended Q3 with $273.5 million in cash and $80 million in unused revolving credit capacity.

Outlook and guidance

• Full-year revenue guidance unchanged, expecting at least $792 million, above prior year.

• Q4 revenue expected to decline sequentially due to earlier-than-anticipated manufacturer solutions deal closures.

• Full-year adjusted EBITDA projected to grow 2%-6% over 2024, with margins in line with year-to-date trends.

• Manufacturer solutions projected to grow approximately 35% in 2025.

• Near-term pressure on prescription transactions revenue and Monthly Active Consumers expected due to retail pharmacy closures, PBM network changes, and integrated savings program volume reductions, with an estimated $35–$40 million revenue impact in 2025.